DDF

Debbie's Dream Foundation: Curing Stomach Cancer Supports Pioneering Gastroesophageal Cancer Research Retreat

Retrieved on: 
Wednesday, May 8, 2024
Education, Organization, GEC, Partnership, Research, Stomach cancer, DRS, MSK, Patient advocacy, Samuel, Health, EST, Quality of life, DDF, Pharmaceutical industry

NEW YORK, May 8, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is proud to announce its collaboration with Memorial Sloan Kettering Cancer Center (MSK) at the upcoming Gastroesophageal Cancer Research Center Retreat. This invitation-only event will occur on Friday, May 10, 2024, from 8:00 a.m. to 6:00 p.m. EST and will feature impactful discussions among leading Gastroesophageal Cancer (GEC) researchers. The program will be led by esteemed figures such as Drs. Yelena Janjigian, Smita Joshi, and Samuel Cytryn, who are at the forefront of GEC research and patient care at MSK. DDF will participate in the retreat's Patient Advocacy and Case Discussion, which will take place at 5:00 p.m. EST, as a key supporter and a pioneering patient advocacy group.

Key Points: 
  • NEW YORK, May 8, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is proud to announce its collaboration with Memorial Sloan Kettering Cancer Center (MSK) at the upcoming Gastroesophageal Cancer Research Center Retreat.
  • Yelena Janjigian, Smita Joshi, and Samuel Cytryn, who are at the forefront of GEC research and patient care at MSK.
  • This incredible collaboration builds on DDF and MSK's partnership for the "Debbie's Dream Early Career Investigator in Gastroesophageal Cancer" fellowship announced earlier this year.
  • The three-year fellowship will be executed under the leadership of Dr. Yelena Janjigian at MSK, emphasizing both organizations' commitment to pioneering cancer research and education.

Doing Digital Awards Honored Digital Pioneers: Brett King, Chris Skinner, Dirk Ohlmeier and Others

Retrieved on: 
Wednesday, April 17, 2024
Public sector, AI, Fintech, SPRING, Digital, ISAA, DDA, Bank, Central bank, Digital platform, DDF, Award, Cryptocurrency

YEREVAN, Armenia, April 17, 2024 (GLOBE NEWSWIRE) -- The Doing Digital Awards (DDA) was launched as a key side-event of SPRING PR's annual Doing Digital Forum.

Key Points: 
  • YEREVAN, Armenia, April 17, 2024 (GLOBE NEWSWIRE) -- The Doing Digital Awards (DDA) was launched as a key side-event of SPRING PR's annual Doing Digital Forum.
  • "Doing Digital Forum has evolved into a groundbreaking tradition where we gather with fellow change-makers, and thought leaders keen to exchange knowledge and expertise, propelling innovation forward.
  • Celebrating excellence in digitalization, the Doing Digital Awards have recognized pioneers like Brett King, Chris Skinner and Dirk Ohlmeier for their transformative impact on banking, fintech and talent growth.
  • "I hope that 'Doing Digital Awards' will become one of the best recognitions in the field.

Brett King, Henri Arslanian, Dirk Ohlmeier and Mohamed Bardastani: Top Keynote Lineup of Doing Digital Forum 2024

Retrieved on: 
Thursday, March 21, 2024
American University of Armenia, Government, National University of Singapore, Visa, Central bank, American University, Supervisory board, Digital, Business, Central Bank of Armenia, SPRING, AI, Minecraft, Reflexive relation, DDF, Social science

YEREVAN, Armenia, March 21, 2024 (GLOBE NEWSWIRE) -- SPRING PR’s annual international Doing Digital Forum (DDF) returns to the capital of Armenia, Yerevan on April 3, 2024.

Key Points: 
  • YEREVAN, Armenia, March 21, 2024 (GLOBE NEWSWIRE) -- SPRING PR’s annual international Doing Digital Forum (DDF) returns to the capital of Armenia, Yerevan on April 3, 2024.
  • SPRING PR Company is the organizer of the Doing Digital Forum and Ameriabank is the fintech partner.
  • Doing Digital Forum 2024 will serve as an exceptional platform for attendees to meet and learn from the global leading experts.
  • “We’re happy to return to Doing Digital Forum”, states Vardan Amaryan , the Founder of Apricot Capital, the Armenian investment company.

Debbie's Dream Foundation: Curing Stomach Cancer Announce Groundbreaking Research Fellowship Grant for Gastric Cancer Research

Retrieved on: 
Tuesday, March 19, 2024
Partnership, Education, Patient, Biomarker, Research, Helicobacter pylori, AACR, DRS, DDF, Stomach, MSK, Gastrointestinal cancer, Health, Stomach cancer, Pharmaceutical industry

FORT LAUDERDALE, Fla., March 19, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) announces an unprecedented collaboration with Memorial Sloan Kettering Cancer Center (MSK) that marks a significant leap forward in the field of gastric cancer research. Through the visionary efforts and support of DDF, a research fellowship grant has been established at MSK under the guidance of Dr. Yelena Janjigian, Chief of Gastrointestinal Oncology Service at MSK. The "Debbie's Dream Foundation Gastric Cancer Investigator" fellowship will focus on patient care, research, and education specifically for esophageal and gastric cancers. The collaboration is a testament to the shared commitment of DDF and MSK to fueling groundbreaking research and providing top-notch cancer care.

Key Points: 
  • FORT LAUDERDALE, Fla., March 19, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) announces an unprecedented collaboration with Memorial Sloan Kettering Cancer Center (MSK) that marks a significant leap forward in the field of gastric cancer research.
  • The "Debbie's Dream Foundation Gastric Cancer Investigator" fellowship will focus on patient care, research, and education specifically for esophageal and gastric cancers.
  • The collaboration is a testament to the shared commitment of DDF and MSK to fueling groundbreaking research and providing top-notch cancer care.
  • Through the 'Debbie's Dream Foundation Gastric Cancer Investigator fellowship, we aim to make impactful strides in biomarker development, laboratory research, and translational studies in gastroesophageal cancer."

Doing Digital Forum Returns with Brett King as Keynote Speaker

Retrieved on: 
Tuesday, March 12, 2024
Visa, Just, Cryptocurrency, Digital, Business, SPRING, Forum, Acquisition, AI, Quality of life, Minecraft, Fintech, DDF, Collaboration, Social change

The keynote speaker is Brett King , a world-renowned futurist, founder of a groundbreaking banking concept, and bestselling author.

Key Points: 
  • The keynote speaker is Brett King , a world-renowned futurist, founder of a groundbreaking banking concept, and bestselling author.
  • "Doing Digital Forum 2024: Embracing Opportunities" will serve as an exceptional platform for attendees to meet and learn from the global leading experts.
  • Ameriabank, a leading Armenian financial and technology company, is supporting the Doing Digital Forum for the second year.
  • The Doing Digital Forum welcomes all enthusiasts of digital transformation and the advancement of the digital economy.

Debbie's Dream Foundation: Curing Stomach Cancer Hosts a Historic 12th Annual Stomach Cancer Capitol Hill Advocacy Day in 2024

Retrieved on: 
Tuesday, March 5, 2024
Stomach cancer, Bangladesh Technical Education Board, Caregiver, Origin, Jazz Pharmaceuticals, News, Federation, Fiscal year, National Cancer Institute, DDF, Merck & Co., Patient, Congress, FY, Research, Pharmaceutical industry

WASHINGTON, March 5, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer celebrated a historic turnout for its 12th Annual Stomach Cancer Capitol Hill Advocacy Day hosted February 5-7, 2024, in Washington, DC. On the morning of February 6, just as the world learned of country music legend Toby Keith's passing from stomach cancer, nearly 150 advocates demonstrated resilience and determination on Capitol Hill, attending 221 scheduled meetings with lawmakers. The advocates passionately conveyed critical asks, urging Congress to pass the Fiscal Year (FY) 2024 spending bills to prevent disruptions in essential research funding, keep stomach cancer on the Peer Reviewed Cancer Research Program (PRCRP) list for FY 2025, and increase FY 2025 funding to the National Institutes of Health and National Cancer Institute.

Key Points: 
  • WASHINGTON, March 5, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer celebrated a historic turnout for its 12th Annual Stomach Cancer Capitol Hill Advocacy Day hosted February 5-7, 2024, in Washington, DC.
  • Their unwavering support in Congress has significantly raised stomach cancer awareness and has led to increased federal research dollars for stomach cancer.
  • Over the years, DDF's advocacy efforts have resulted in $34.4 million dedicated to stomach cancer research through the PRCRP to date.
  • DDF expresses heartfelt gratitude to all advocates, sponsors, and supporters who contributed to the success of the 12th Annual Stomach Cancer Capitol Hill Advocacy Day.

Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M

Retrieved on: 
Tuesday, February 13, 2024
Biotechnology, FDA, Professional Services, Other Health, Health, Pharmaceutical, Other Science, Research, Science, Clinical Trials, Finance, Therapy, Psoriasis, ALS, Inflammation, TPG, UPMC, Multiple sclerosis, Sudo, Series, DDF, Venture round, Bayer, Patient, TYK2, Investment, Partnership, Pharmaceutical industry

This brings the total raised in this upsized round to $147 million.

Key Points: 
  • This brings the total raised in this upsized round to $147 million.
  • With this second Series B round close, Sudo has raised a total of $188 million since its founding in 2020.
  • Specifically, we see scope to expand beyond MS into Alzheimer’s and ALS,” said Jonathan Behr, Partner, SV Health Investors.
  • Sudo is also developing a potential first and best-in-class topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic diseases.

Groundbreaking Study Demonstrates 20-Year Remission in Pemphigus Vulgaris Patients Using IVIg Therapy

Retrieved on: 
Wednesday, January 31, 2024
Ahmad, Research, Science, Pemphigus vulgaris, National academy, Patient, Avicenna, Immune tolerance, Doctor of Science, MPA, PNAS, FRCP, Immunoglobulin therapy, DDF, Admiration

Researchers from Tufts University School of Medicine (Boston, MA) and Sorbonne Université (Paris, France) have demonstrated a remarkable 20-year clinical and serological remission in patients using a defined protocol of intravenous immunoglobulin (IVIg) therapy.

Key Points: 
  • Researchers from Tufts University School of Medicine (Boston, MA) and Sorbonne Université (Paris, France) have demonstrated a remarkable 20-year clinical and serological remission in patients using a defined protocol of intravenous immunoglobulin (IVIg) therapy.
  • Twenty-one patients with confirmed PV received IVIg therapy according to a specific protocol.
  • This long-term remission suggests that IVIg may help restore immune balance and tolerance in PV patients.
  • The pioneering research, offering sustained remission for pemphigus vulgaris patients, highlights the considerable potential of IVIg therapy.

Debbie's Dream Foundation: Curing Stomach Cancer Celebrates a Year of Impactful Programs and Community Support in 2023

Retrieved on: 
Wednesday, January 3, 2024
Veteran, Stomach, Travel, Amgen, ASCO, Caregiver, DDF, Daiichi Sankyo, Research, Zymeworks, DSI, Copper, Stomach cancer, Federation, Genetics, BMS, United Way, Mind, Patient, Medicine, Bristol Myers Squibb, Club, Pharmaceutical industry

FORT LAUDERDALE, Fla., Jan. 3, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) proudly wraps up an impactful year, delivering crucial resources and support to the stomach cancer community, thanks to the unwavering commitment of 2023 industry partners. The support from generous sponsors has allowed DDF to continue vital programs and initiate new endeavors. This year, DDF worked closely with sponsors such as Amgen, Arcus, Astellas, Bristol Myers Squibb (BMS), Daiichi Sankyo (DSI), Genentech, Lilly Oncology, Merck, Taiho Oncology, and Zymeworks, whose dedication has been instrumental in advancing various programs, ensuring DDF's continued service to patients, their families, and caregivers.

Key Points: 
  • FORT LAUDERDALE, Fla., Jan. 3, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) proudly wraps up an impactful year, delivering crucial resources and support to the stomach cancer community, thanks to the unwavering commitment of 2023 industry partners.
  • The support from generous sponsors has allowed DDF to continue vital programs and initiate new endeavors.
  • At the top of the year, DDF hosted its Inaugural Patient Advocate Retreat during its 11th Annual Stomach Cancer Capitol Hill Advocacy Day in Washington, D.C.
  • For the 2023 Symposia series, DDF collaborated with Moffitt Cancer Center in Tampa, Florida, to host a Stomach Cancer Educational Symposium.

Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases

Retrieved on: 
Tuesday, November 28, 2023
Biology, RNA, DDF, HD, Therapy, FAN1, Neurodegenerative disease, RNA Biology, Harness, Patient, Pharmaceutical industry

Cambridge, UK, 28th November 2023: Harness Therapeutics (‘Harness’, previously Transine Therapeutics), a biotechnology company focused on physiological protein upregulation to develop next generation therapeutics for the treatment of neurodegenerative diseases, announces that it has successfully raised an additional £4 million in funding from its existing investors, bringing the total invested to £17.6 million.

Key Points: 
  • Cambridge, UK, 28th November 2023: Harness Therapeutics (‘Harness’, previously Transine Therapeutics), a biotechnology company focused on physiological protein upregulation to develop next generation therapeutics for the treatment of neurodegenerative diseases, announces that it has successfully raised an additional £4 million in funding from its existing investors, bringing the total invested to £17.6 million.
  • Proceeds will be used to advance Harness’ lead Huntington’s Disease (HD) programme targeting FAN1 nuclease and pursue target discovery and validation activities in other neurodegenerative disease pathways.
  • There is a pressing need for new approaches in neurodegeneration where compelling targets could be unlocked by controlled upregulation,” said Dr Jan Thirkettle, CEO of Harness Therapeutics.
  • From this work, the company has gained unique insights into the regulation of therapeutic targets and broadened its oligonucleotide based toolset for physiological protein upregulation.